Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Humacyte Coronary Tissue Engineered Vessel (CTEV)
Humacyte Coronary Tissue Engineered Vessel · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Humacyte Coronary Tissue Engineered Vessel (CTEV) | EXPERIMENTAL | Surgically implanted CTEV for CABG |
| Name | Type | Description |
|---|---|---|
| Humacyte Coronary Tissue Engineered Vessel (CTEV) | BIOLOGICAL | The CTEV is a tissue-engineered acellular vascular conduit regulated as a biological product by the Food and Drug Administration (FDA). The CTEV has an inner diameter of 3.5 mm and with approximately 20 cm of usable length. |
Inclusion Criteria: 1. Age ≥18 years with the ability to provide written informed consent. 2. Planned first isolated CABG surgery for atherosclerotic coronary artery disease with a planned LIMA graft to the LAD and at least one other planned vessel bypass. 3. An RCA or LCx territory target vessel f...
Humacyte Coronary Tissue Engineered Vessel (CTEV) is an investigational therapy being studied for use in patients with coronary artery disease who require coronary artery bypass grafting (CABG). It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Humacyte Coronary Tissue Engineered Vessel is being developed by Humacyte, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol HUMA. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational vessel for coronary artery bypass grafting.
Humacyte Coronary Tissue Engineered Vessel is in Phase 2 clinical development. It is an investigational product, meaning it has not yet been approved for commercial use. The ongoing Phase 2 trial is designed to evaluate its safety and efficacy in patients with coronary artery disease requiring CABG.
Humacyte Coronary Tissue Engineered Vessel is being evaluated in a Phase 2 clinical trial registered as NCT07730528. This study is designed to assess the safety and efficacy of the vessel in patients with coronary artery disease requiring coronary artery bypass grafting. The trial is not yet recruiting and plans to enroll approximately 10 participants.
Yes, Humacyte Coronary Tissue Engineered Vessel is also known as Humacyte Coronary Tissue Engineered Vessel (CTEV). The abbreviation CTEV is used interchangeably with the full name in clinical trial documentation and research contexts.